3 Active Studies

Premature Birth Clinical Trials Near You

Find 3 actively recruiting premature birth research studies near you. Connect with study sites, check eligibility, and explore new treatment options.

3
Active Trials
18+
Locations
2,283
Participants Needed

Recruiting Studies

Top Cities for Premature Birth Clinical Trials

Premature Birth clinical trials are recruiting across 18 cities. Here are the cities with the most active studies:

About Premature Birth

Premature birth is delivery before 37 weeks of pregnancy and is the leading cause of infant death and disability worldwide. Complications can affect the brain, lungs, and other developing organs. Prevention strategies include progesterone therapy, cervical cerclage, and prenatal care.

Clinical trials are advancing new treatments for premature birth. Currently, 3 studies are recruiting a combined 2,283 participants across the United States. Research is being conducted by 3 organizations including The George Washington University Biostatistics Center, University of Washington, University of California, San Diego.

2026 Premature Birth Research Landscape

As of March 2026, the premature birth clinical trial landscape includes 3 actively recruiting studies across 18 cities in the United States. These studies are collectively seeking 2,283 participants, with an average enrollment target of 761 per study.

Research is being led by 3 different organizations, including The George Washington University Biostatistics Center, University of Washington, University of California, San Diego.

Geographically, premature birth trials are most concentrated in Birmingham, Alabama (2 trials); Auckland, (2 trials); San Francisco, California (1 trial); Chicago, Illinois (1 trial); New York, New York (1 trial) and 7 other cities.

Featured Premature Birth Studies

Highlighted recruiting studies for premature birth, selected by enrollment size and research scope.

RecruitingNCT06980025

Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial

This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery o...

Sponsor: The George Washington University Biostatistics Center· 1,800 participants· 10 locations (Birmingham, San Francisco, Chicago, New York)
View full study details →
RecruitingNCT06893939

Limited Versus Extended Trophic Feeding (LET-FEED) Trial

Study Hypothesis/Question In infants born very preterm, advancing enteral feeds after 24 hours from birth (limited trophic feeds) versus after 72 hours (extended trophic feeds) reduces the risk of all-cause late onset sepsis (LOS) without increasing the risk of other adverse outcomes. Study Design Type This is a multi-center, open-label, parallel-group, individual randomized controlled trial comp...

Sponsor: University of Washington· 350 participants· 6 locations (Birmingham, Tampa, Oklahoma City, Houston)
View full study details →
RecruitingNCT05610085

A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures

The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly greater than 60mg/kg. This study will be an open label dose-escalation, preliminary safety and efficacy study. There will be a randomized control treatment component. Inf...

Sponsor: University of California, San Diego· 133 participants· 4 locations (San Diego, Minneapolis, Auckland, Auckland)
View full study details →

Frequently Asked Questions About Premature Birth Clinical Trials

Are there premature birth clinical trials near me?

Yes, there are 3 premature birth clinical trials currently recruiting across 18+ cities in the United States, including Birmingham, Alabama; Auckland, ; San Francisco, California. Browse the studies above to find one at a location convenient for you.

How do I join a premature birth clinical trial?

To join a premature birth clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.

Are premature birth clinical trials free?

Yes, participation in premature birth clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.

What types of premature birth treatments are being studied?

Current premature birth clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 3 research organizations.

Is it safe to participate in premature birth clinical trials?

Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.

Data updated March 1, 2026 from ClinicalTrials.gov

About This Data

Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.

Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.

Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov